- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04654611
Tafluprost Preservative Free Switch Study
Ocular Surface Conditions in Asian Glaucoma Patients With Existing Corneal Disorders Switching From Preserved Prostaglandin Analogues Monotherapy to Preservative-free Tafluprost
Study Overview
Status
Intervention / Treatment
Detailed Description
Importance: Glaucoma medications are often preserved with agents such as benzalkonium chloride, which commonly lead to ocular surface diseases.
Background: To investigate the effect of switching to a preservative-free prostaglandin analogue, tafluprost 0.0015% on treatment tolerability and ocular surface diseases.
Design: This was a prospective, open label, non-randomised, observational study performed in a single hospital.
Participants: Patients of Asian descent who have primary open angle glaucoma and ocular hypertension (n = 28), who received preserved prostaglandin monotherapy for longer than 3 months, and has a National Eye Institute ocular surface staining scale score higher than 1.
Methods: Patients were switched from preserved prostaglandin monotherapy to preservative-free tafluprost 0.0015%. Patients were analysed at baseline (Visit 0), 1 month (Visit 1) and 3 months (Visit 2).
Main Outcome Measures: The main parameter measured is the change in the fluorescein staining score at Visit 2.
Study Type
Enrollment (Actual)
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
Selangor Darul Ehsan
-
Petaling Jaya, Selangor Darul Ehsan, Malaysia, 46200
- THONEH
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Age of 21 years or older and those who can provide informed consent.
- Patients who have corneal disorders due to the prostaglandin usage. (At least one eye must have a score above 1 on the NEI scale)
- Intraocular pressure (IOP) ≤ 21 mm Hg in the study eye at the screening examination (under treatment)
- If only one eye is eligible, it is to be evaluated. If both eyes are eligible, then the eye with a higher NEI score will be selected for evaluation.
- Pretreatment must be monotherapy with any of the following preserved ophthalmic solutions; latanoprost, travoprost, bimatoprost or tafluprost and its period must be longer than 3 months.
- Outpatients who can visit the clinic on the designated day as instructed by the physician.
- A best-corrected ETDRS visual acuity score of +0.6 logMAR (Snellen equivalent of 20 ⁄ 80) or better in each eye.
Exclusion Criteria:
- Those with severe visual field disorder (Mean deviation of 15 dB or worse)
- Those with a history of ocular surgeries (such as corneal refractive surgery, intraocular surgery including ocular laser treatment which may affect the patient's ocular surface condition) within 6 months prior to the study initiation.
- Those with severe dry eye (those in need of drug to treat dry eye), ocular allergy, ocular infection or ocular inflammation
- Those who need to use systemic or ophthalmic steroids (excluding topical skin steroidal ointment) and anti-glaucoma agents other than latanoprost, travoprost, bimatoprost or preservative free tafluprost ophthalmic solution
- Female patients who are pregnant, nursing or lactating
- Those with a history of drug allergy (hypersensitivity) to the drugs to be used during the study period (anesthetic ophthalmic solution, fluorescein, etc.) or similar drugs to the investigational product
- Those who need to wear contact lenses during the study period
- Any corneal abnormality or other condition preventing reliable applanation tonometry
- Anterior chamber angle less than grade 2 according to Schaffer classification as measured by Gonioscopy
- Any uncontrolled systemic disease (e.g. hypertension, diabetes)
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Other: Treatment group
The intervention will be preservative free tafluprost 0.0015% topical ophthalmic solution given once daily for the study duration.
|
preservative free prostaglandin analogue option for treatment of primary open angle glaucoma and ocular hypertension patients
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Changes in the fluorescein staining score (NEI) at Visit 2
Time Frame: 3 months
|
The fluorescein stained area of the cornea will be measured according to the National Eye Institute/Industry (NEI/I) method.
NEI grading scale consists of a grid that divides the corneal area into five sections, each of which is assigned a score between zero and 3 depending of the amount and distribution of Corneal Fluorescein Stain (CFS); the total CFS score ranges from 0/15 (absence of corneal epitheliopathy) to 15/15 (severe epitheliopathy)
|
3 months
|
Collaborators and Investigators
Investigators
- Principal Investigator: Hsien Han Lim, Tun Hussein Onn National Eye Hospital
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 001 (NavyGHB)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Primary Open Angle Glaucoma
-
Omar SaidCompletedGlaucoma,Primary Open-Angle ,Primary Angle ClosureEgypt
-
Glaucot Teknoloji Anonim SirketiRecruitingPrimary Open-Angle GlaucomaTurkey
-
China Medical University HospitalCompletedEffect of Acupuncture on Visual Acuity and Visual Field in Patients With Primary Open-angle GlaucomaPrimary Open-angle GlaucomaTaiwan
-
InnFocus Inc.CompletedPrimary Open-angle GlaucomaSpain, United States, United Kingdom, France, Italy
-
Glaukos CorporationTerminatedPrimary Open-Angle GlaucomaUnited States
-
Rehab mahmoud abdelhamid mohamedCairo UniversityCompletedPrimary Open-angle GlaucomaEgypt
-
Cairo UniversityUniversity of LuebeckUnknown
-
Xiaodong ZhouCompletedPrimary Open-angle Glaucoma
-
Qlaris Bio, Inc.RecruitingPrimary Open Angle Glaucoma of Both Eyes | Primary Open Angle Glaucoma (POAG) | Primary Open-Angle Glaucoma, Unspecified Eye | Ocular Hypertension (OHT)United States
-
Peking UniversityRecruitingPrimary Open Angle Glaucoma | Ocular Hypertension | Primary Open Angle Glaucoma of Both Eyes | Primary Open-Angle Glaucoma, Unspecified Eye | Suspect GlaucomaChina
Clinical Trials on preservative free tafluprost 0.0015%
-
Santen OyCompleted
-
Santen Inc.CompletedA Study Assessing the Safety and Efficacy of DE-117 Ophthalmic Solution in Patients With POAG or OHTGlaucoma and Ocular HypertensionUnited States
-
Santen OyCompletedOcular Hypertension | Open-Angle GlaucomaFinland, Germany
-
Santen OyCompletedOcular Hypertension | GlaucomaUnited Kingdom, United States
-
Alexandria UniversityCompleted
-
Merck Sharp & Dohme LLCCompletedOcular Hypertension | Glaucoma
-
Universitaire Ziekenhuizen KU LeuvenAllerganUnknownOcular Hypertension | GlaucomaBelgium, Austria, Italy, Switzerland, United Kingdom
-
FinnMedi OyTampere University; The Laboratory and Pharmacy Public Utility of the Pirkanmaa...CompletedOcular Hypertension | Open-Angle GlaucomaFinland
-
Gangnam Severance HospitalCompletedPrimary Open-angle Glaucoma
-
Santen Pharmaceutical Co., Ltd.CompletedOpen-angle Glaucoma, Ocular HypertensionChina